查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1466262

連續生物加工市場：按產品、製程、應用、業務規模、最終用戶分類 - 2024-2030 年全球預測

Continuous Bioprocessing Market by Product (Bioreactors, Cell Culture Media & Reagent, Centrifuges), Process (Downstream Bioprocess, Upstream Bioprocess), Application, Scale of Operation, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年連續生物加工市場規模為2.3344億美元，2024年將達2.8242億美元，2030年將達9.0223億美元，複合年成長率為21.30%。

連續生物加工代表了疫苗、單株抗體和治療性蛋白質等生物製藥生產的模式轉移。連續生物加工允許材料和產品在整個生產週期中不間斷地流動，從而提高效率、品管和可擴展性，這與傳統的批量加工不同，傳統的批量加工可以預期在單獨的步驟中加工固定數量的產品。製藥業正在不斷發展，政府對該領域的支持是連續生物加工成長的關鍵驅動力。超批量加工和一次性技術的引入帶來的好處不斷增加，以及對生物製藥生產的持續需求，正在刺激連續生物加工技術的採用。相較之下，高昂的設備成本、操作困難以及對製程變化的擔憂對生物製程的持續採用提出了挑戰。此外，必須考慮監管因素，因為連續生物過程可能需要新的驗證策略才能符合衛生當局製定的嚴格標準。然而，一些市場供應商正在投資研發，以解決連續生物加工技術中的許多營運挑戰，並為進一步的市場擴張做好準備。此外，灌注的採用與一次性設備相關，基質細胞製造的連續生物製程方法的市場開拓預計將在未來幾年顯著促進整體市場成長。

主要市場統計
基準年[2023] 2.3344億美元
預測年份 [2024] 2.8242億美元
預測年份 [2030] 9.0223億美元
複合年成長率（%） 21.30%

產物：在重組蛋白的大規模生產中越來越偏好反應器

反應器是發生生物反應的容器，特別適用於培養細菌、酵母菌和哺乳動物細胞等生物。這對於擴大生物製程規模至關重要。細胞培養基和試劑列出了生物過程中細胞生長和產物表現所需的必需營養素。離心機用於根據混合物的密度分離混合物的成分。在生物加工中，它對於細胞澄清和產品回收至關重要。層析法系統用於精製生物產品。連續層析法技術，包括模擬移動床 (SMB) 系統，可提供高生產率和層析法介質的高效使用，從而降低耗材成本。過濾系統對於製程流體的滅菌和澄清至關重要，確保去除雜質和污染物。培養箱和搖床對於最佳化細胞培養生長條件、控制溫度、濕度和攪拌至關重要。混合系統確保反應器和儲存罐內的均勻性，並影響細胞生長、營養分佈和產物形成的一致性。相較之下，連續反應器可以不間斷地運作，確保產品品質一致並可能降低製造成本，而連續離心機可以不間斷地加工生物產品，提高效率和一致性。

流程：由於效率和產能的提高，上游工程的使用增加

上游工程構成生物生產的初始階段，涉及適合微生物、植物和哺乳動物細胞生長和繁殖的環境的開發和維護。此步驟通常包括培養基製備、細胞培養、細胞儲存和初次回收。在上游工程之後，下游生物過程精製並製備這些生物產品以供最終使用或進一步配製。由於生物製品固有的複雜性和多樣性，下游加工通常需要複雜的分離和精製技術，例如離心、過濾和層析法。上游和下游生物過程對於最終產品的生產率和品質都很重要。然而，它們的主要目的、複雜性和挑戰差異很大。上游著重於培養細胞培養和增殖的最佳環境，下游著重於所得產物的精製和精製。

應用：在疫苗產業廣泛使用連續生物製程來改善公眾健康

細胞和基因治療中的連續生物加工利用尖端技術來產生個人化治療。該領域的優勢包括減少批次差異、提高可擴展性以及提高產品一致性。連續生產單株抗體的製程可減少勞動力和設施佔地面積，並實現即時品質監控，提高生產率和成本效益。在疫苗行業，由於大流行期間需要快速開發和部署以及流感等季節性疫苗的生產，對連續生物加工的興趣正在增加。連續生物加工可以顯著縮短開發時間並提高對公共衛生需求的應對力。相較之下，連續加工提供了提高疫苗加工集約化、穩定性和產量的機會。

業務規模：擴大連續生物加工在臨床業務的應用

臨床業務對於連續生物加工至關重要，對開發的生技藥品的功效和品質具有至關重要的影響。它涵蓋廣泛的活動，從早期臨床試驗到遵守藥物安全性和有效性監管指南的程序。連續生物加工的商業運作圍繞著大規模實施該工藝以實現商業化和銷售的實用性。目標是擴大生產規模並確保一致的品質、成本效益和法規遵循。連續生物加工為簡化生物製藥生產提供了一種有前途的方法，但其實施在規模、臨床和商業業務存在很大差異。

最終用戶：連續生物加工在 CDMO 中的作用非常重要，它優先考慮彈性和增強向客戶提供的服務。

學術和研究機構通常專注於連續生物加工的基礎科學和概念驗證研究。這些機構透過進行創新研究並經常與產業合作夥伴合作，在推動技術進步方面發揮著至關重要的作用。受託製造廠商描述了向製藥和生物技術公司外包開發和製造服務。它們是藥品供應鏈不可或缺的一部分，擴大採用連續生物加工來實現產品差異化並提高成本效率。製藥和生物技術公司是推動連續生物製程商業性實施的主要最終用戶。另一方面，學術和研究機構透過出版物、專利和熟練專業人員的培訓為連續生物加工做出貢獻。與研究機構不同，CDMO 投資於可擴展且適應性強的技術，可以支援多種產品和流程，從而為客戶最佳化上市時間。與學術機構和 CDMO 不同，製藥和生物技術公司既進行內部產品開發又進行商業生產。

區域洞察

在美洲地區，對生物製造創新的濃厚興趣、對生物技術領域的大量投資以及鼓勵先進製造技術的法規環境正在推動連續生物加工的採用。隨著主要製藥公司和生物風險公司尋求更高效、更具成本效益和可擴展的製造程序，連續生物加工代表了一種競爭優勢。此外，強大的技術基礎設施和熟練勞動力的存在正在促進美洲從傳統批量工藝向連續方法的轉變。此外，在歐洲、中東和非洲，高昂的營運成本和嚴格的監管標準導致公司採用連續生物製程來降低成本並提高生技藥品的品質。歐洲製藥業以注重創新和永續性而聞名，這反映在快速成長的生物相似藥市場。此外，中東和非洲也開始採用此類流程。由於對生物製藥的需求不斷成長以及藥品生產能力本地化的努力，連續生物加工預計將在該地區成長。在亞太地區，由於生物製藥行業的快速擴張和全球競爭的需要，連續生物加工的採用正在迅速增加。越來越多的患者需要高品質的生技藥品，生物技術公司不斷增加投資，並支持政府旨在提高生物製造能力的措施。一些國家對實施連續流程以加快藥物開發和製造時間表、減少製造足跡並節省成本，同時遵守國際品質標準表現出了濃厚的興趣。

FPNV定位矩陣

FPNV定位矩陣對於評估連續生物加工市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限。最前線 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對連續生物加工市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該細分市場競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、碎片化主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：包括新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：包括對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.連續生物加工市場的市場規模與預測是多少？

2. 在連續生物加工市場的預測期內，我們應該考慮投資哪些產品和應用？

3.連續生物加工市場的技術趨勢和法規結構是什麼？

4.連續生物加工市場主要供應商的市場佔有率為何？

5. 進入連續生物加工市場的適當型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 生物製藥需求增加以及政府對該行業的支持
      • 採用批量處理和一次性技術帶來的更多好處
      • 工業4.0的到來以及自動化數位化的趨勢
    • 抑制因素
      • 連續生物加工的嚴格法規和高昂的設備成本
    • 機會
      • 採用與一次性設備結合的灌注
      • 開發基質細胞生產的連續生物製程方法
    • 任務
      • 操作困難和流程變更問題
  • 市場區隔分析
    • 產品：反應器在大規模重組蛋白生產中日益普及
    • 流程：由於效率和產能的提高，上游流程的使用增加
    • 應用：透過在疫苗產業廣泛使用連續生物製程來改善公眾健康
    • 業務規模：擴大連續生物加工在臨床業務的應用
    • 最終用戶：連續生物加工發揮關鍵作用，因為 CDMO 優先考慮彈性和增強的客戶服務
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章連續生物加工市場：依產品

  • 介紹
  • 反應器
  • 細胞培養基和試劑
  • 離心機
  • 層析法系統
  • 過濾系統
  • 培養箱和搖床

第7章連續生物加工市場：依製程分類

  • 介紹
  • 下游生物過程
  • 上游生物程序

第8章連續生物加工市場：依應用分類

  • 介紹
  • 細胞/基因治療
  • 單株抗體
  • 疫苗

第9章連續生物製程市場：依業務規模

  • 介紹
  • 臨床
  • 商業的

第10章連續生物加工市場：依最終用戶分類

  • 介紹
  • 學術研究所
  • 合約開發和製造組織
  • 製藥和生物技術公司

第11章美洲連續生物處理市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太連續生物加工市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的連續生物加工市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

第15章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-033F7A232457

[189 Pages Report] The Continuous Bioprocessing Market size was estimated at USD 233.44 million in 2023 and expected to reach USD 282.42 million in 2024, at a CAGR 21.30% to reach USD 902.23 million by 2030.

Continuous bioprocessing represents a paradigm shift in the production of biopharmaceutical products, such as vaccines, monoclonal antibodies, or therapeutic proteins. Continuous bioprocessing allows for the uninterrupted flow of materials and products through the production cycle, offering potential improvements in efficiency, quality control, and scalability, unlike traditional batch processing, which processes a fixed volume of products in discrete steps. Pharmaceutical industries are advancing, and government support for the sector is the principal driver of growth for continuous bioprocessing. Increased benefits of over-batch processing & uptake of single-use technology and the continued demand for the production of biopharmaceutical products are spurring the adoption of continuous bioprocessing technologies. In contrast, high equipment costs, operational difficulties, and process change concerns pose a challenge to adopting a continuous bioprocess. In addition, regulatory considerations must be managed, as continuous bioprocessing may necessitate new validation strategies to comply with the stringent standards set by health authorities. However, several market vendors invest in research and development to address many operational challenges in the continuous bioprocessing technologies and further chart to expand the market. Moreover, the adoption of perfusion is associated with single-use equipment, and the development of a continuous bioprocessing approach to stromal cell manufacturing is expected to enhance overall market growth in the coming years significantly.

KEY MARKET STATISTICS
Base Year [2023] USD 233.44 million
Estimated Year [2024] USD 282.42 million
Forecast Year [2030] USD 902.23 million
CAGR (%) 21.30%

Product: Growing preference for bioreactors in large-scale production of recombinant proteins

Bioreactors are vessels in which biological reactions are carried out, especially for culturing organisms such as bacteria, yeast, and mammalian cells. They are crucial for scaling up bioprocessing. Cell culture media and reagents provide the essential nutrients required for cell growth and product expression in bioprocessing. Centrifuges are utilized to separate components of a mixture based on their density. In bioprocessing, they are essential for cell clarification and product recovery. Chromatography systems are employed for the purification of biological products. Continuous chromatography technologies, including simulated moving bed (SMB) systems, offer higher productivity and better utilization of chromatography media, reducing the cost of consumables. Filtration systems are imperative for sterilizing and clarifying process fluids, warranting the removal of impurities and contaminants. Incubators and shakers are vital for optimizing growth conditions for cell cultures, providing control over temperature, humidity, and agitation. Mixing systems ensure homogeneity in bioreactors and holding tanks, influencing cell growth, nutrient distribution, and product formation consistency. In comparison, continuous bioreactors operate without interruption, ensuring consistent product quality and potentially lower manufacturing costs, and continuous centrifuges allow for the uninterrupted processing of bioproducts, enhancing efficiency and consistency.

Process: Rising usage of upstream processes owing to progress in terms of efficiency and capacity

Upstream processing, constituting the initial steps of bioproduction, involves developing and maintaining a suitable environment for the growth and multiplication of microbial cells, plant, or mammalian cells. This phase often includes media preparation, cell culture, cell preservation, and primary recovery. Downstream bioprocessing, which follows the upstream step, involves purifying these biological products, and preparing them for their final use or further formulation. Due to inherent complexity and diversity of biological products, downstream processes typically entail complex separation and purification techniques, including centrifugation, filtration, chromatography and more. Both upstream and downstream bioprocessing are critical for both productivity and quality of end products. However, they differ significantly in their chief objectives, complexities, and challenges. Upstream focuses on fostering an optimal environment for cell culture and propagation, while downstream is centered around the purification and refinement of the resultant product.

Application: Extensive utilization of continuous bioprocessing in the vaccine industry to improve public health

Continuous bioprocessing in cell and gene therapies involves using cutting-edge techniques to manufacture personalized treatments. This sector benefits from reduced batch-to-batch variability, enhanced scalability, and improved product consistency. Continuous processes for manufacturing monoclonal antibodies increase productivity and cost-effectiveness due to reduced labor and facility footprint and the potential for real-time quality monitoring. The vaccine industry is experiencing a growing interest in continuous bioprocessing, given the need for rapid development and deployment during pandemics and the production of seasonal vaccines, such as those for influenza. Continuous bioprocessing can substantially shorten development times and improve responsiveness to public health needs. In comparison, continuous processing offers opportunities for enhancing process intensification, stability, and throughput for vaccines.

Scale of Operation: Growing application of continuous bioprocessing in the clinical operations

Clinical operations are integral to continuous bioprocessing, pivotally influencing the efficacy and quality of the developed biologics. It encapsulates a broad range of activities, from early-stage clinical trials to procedures adhering to regulatory guidelines for the safety and efficacy of medicinal products. Commercial operations in continuous bioprocessing revolve around the practicality of implementing the processes on a large scale for commercialization and sale. It's about scaling up production and ensuring consistent quality, cost-effectiveness, and regulatory compliance. While continuous bioprocessing presents a promising approach to streamline biopharmaceutical production, its implementation differs widely across the scale, clinical, and commercial operations.

End-User: Significant role of continuous bioprocessing in CDMO as they prioritize flexibility and service offering enhancements for their clients

Academic and research institutes often focus on fundamental science and proof-of-concept studies in continuous bioprocessing. They are crucial in advancing technology by conducting innovative research, often collaborating with industry partners. Contract development & manufacturing organizations offer outsourced development and manufacturing services to pharmaceutical and biotech companies. They are an integral part of the pharmaceutical supply chain and increasingly incorporate continuous bioprocessing to differentiate their offerings and improve cost efficiencies. Pharmaceutical and biotechnology companies are the primary end-users driving the commercial implementation of continuous bioprocessing. In comparison, academic and research institutes contribute to the continuous bioprocessing through publications, patents, and training of skilled professionals. In contrast to research institutes, CDMOs invest in scalable and adaptable technologies that can cater to multiple products and processes, optimizing time-to-market for their clients. Pharmaceutical & biotechnology companies carry out both in-house product development and commercial production, unlike academic institutes or CDMOs.

Regional Insights

In the American region, the adoption of continuous bioprocessing is driven by a strong focus on innovation in biomanufacturing, significant investments in the biotech sector, and a regulatory environment encouraging advanced production techniques. With major pharmaceutical companies and biotech startups striving to achieve more efficient, cost-effective, and scalable manufacturing processes, continuous bioprocessing offers a competitive advantage. Additionally, the presence of a robust technological infrastructure and highly skilled workforce has facilitated the transition from traditional batch processes to continuous approaches in the Americas. Furthermore, in EMEA, high operational costs and stringent regulatory standards have pushed companies to adopt continuous bioprocessing to reduce costs and enhance the quality of biologics. The European pharmaceutical landscape is known for its strong emphasis on innovation and sustainability, which is further reflected in its rapidly growing biosimilar market, where continuous bioprocessing delivers substantial benefits in terms of production agility and speed to market. Additionally, adopting such processes is nascent in the Middle East and Africa. In this region, the continuous bioprocessing is expected to grow by the increasing need for biologics and efforts to localize pharmaceutical production capabilities. The APAC region has seen a surge in adopting continuous bioprocessing due to its rapidly expanding biopharmaceutical sector and the need to compete globally. A growing patient population needs high-quality biologics, increasing investments from players in biotechnology, and supportive government initiatives aiming to boost biomanufacturing capabilities. Several countries have demonstrated significant interest in incorporating continuous processes to accelerate drug development and production timelines, reduce manufacturing footprints, and enable cost savings, all while complying with international quality standards.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Continuous Bioprocessing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Continuous Bioprocessing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Continuous Bioprocessing Market, highlighting leading vendors and their innovative profiles. These include 3D Biotek LLC, 3M Company, Adolf Kuhner AG, bbi-biotech GmbH, Belach Bioteknik AB, Bio-Rad Laboratories, Inc., Bionet Servicios Tecnicos S.L., Colder Products Company, Danaher Corporation, Esco Aster Pte Ltd., Esco VacciXcell, FiberCell Systems Inc., Fujifilm Holdings Corporation, GE HealthCare Technologies Inc., GEA Group, Getinge AB, Infors AG, Merck KGaA, Repligen Corporation, Sartorius AG, simAbs NV, Suzhou Transcenta Therapeutics Co., Ltd., Thermo Fisher Scientific Inc., Watson-Marlow Fluid Technology Group, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Continuous Bioprocessing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Bioreactors
    • Cell Culture Media & Reagent
    • Centrifuges
    • Chromatography System
    • Filtration Systems
    • Incubators & Shakers
  • Process
    • Downstream Bioprocess
    • Upstream Bioprocess
  • Application
    • Cell & Gene Therapy
    • Monoclonal Antibodies
    • Vaccines
  • Scale of Operation
    • Clinical Operations
    • Commercial Operations
  • End-User
    • Academic & Research Institutes
    • Contract Development & Manufacturing Organizations
    • Pharmaceutical & Biotechnology Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Continuous Bioprocessing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Continuous Bioprocessing Market?

3. What are the technology trends and regulatory frameworks in the Continuous Bioprocessing Market?

4. What is the market share of the leading vendors in the Continuous Bioprocessing Market?

5. Which modes and strategic moves are suitable for entering the Continuous Bioprocessing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for biopharmaceuticals & government support for the industry
      • 5.1.1.2. Increased benefits over batch processing & uptake of single-use technology
      • 5.1.1.3. Advent of industry 4.0 & trend towards automation & digitization
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulations for continuous bioprocessing coupled with high equipment cost
    • 5.1.3. Opportunities
      • 5.1.3.1. Adoption of perfusion associated with single-use equipment
      • 5.1.3.2. Development of a continuous bioprocessing approach to stromal cell manufacturing
    • 5.1.4. Challenges
      • 5.1.4.1. Issues with operational difficulties and process changes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Growing preference for bioreactors in large-scale production of recombinant proteins
    • 5.2.2. Process: Rising usage of upstream processes owing to progress in terms of efficiency and capacity
    • 5.2.3. Application: Extensive utilization of continuous bioprocessing in the vaccine industry to improve public health
    • 5.2.4. Scale of Operation: Growing application of continuous bioprocessing in the clinical operations
    • 5.2.5. End-User: Significant role of continuous bioprocessing in CDMO as they prioritize flexibility and service offering enhancements for their clients
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Continuous Bioprocessing Market, by Product

  • 6.1. Introduction
  • 6.2. Bioreactors
  • 6.3. Cell Culture Media & Reagent
  • 6.4. Centrifuges
  • 6.5. Chromatography System
  • 6.6. Filtration Systems
  • 6.7. Incubators & Shakers

7. Continuous Bioprocessing Market, by Process

  • 7.1. Introduction
  • 7.2. Downstream Bioprocess
  • 7.3. Upstream Bioprocess

8. Continuous Bioprocessing Market, by Application

  • 8.1. Introduction
  • 8.2. Cell & Gene Therapy
  • 8.3. Monoclonal Antibodies
  • 8.4. Vaccines

9. Continuous Bioprocessing Market, by Scale of Operation

  • 9.1. Introduction
  • 9.2. Clinical Operations
  • 9.3. Commercial Operations

10. Continuous Bioprocessing Market, by End-User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Contract Development & Manufacturing Organizations
  • 10.4. Pharmaceutical & Biotechnology Companies

11. Americas Continuous Bioprocessing Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Continuous Bioprocessing Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Continuous Bioprocessing Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale
    • 14.3.2. Sartorius and Repligen Launch Integrated Bioreactor System
    • 14.3.3. 3M To Invest Nearly USD 150 Million To Advance Capabilities In Biopharma Filtration Technology
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CONTINUOUS BIOPROCESSING MARKET RESEARCH PROCESS
  • FIGURE 2. CONTINUOUS BIOPROCESSING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CONTINUOUS BIOPROCESSING MARKET DYNAMICS
  • FIGURE 7. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. CONTINUOUS BIOPROCESSING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. CONTINUOUS BIOPROCESSING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CONTINUOUS BIOPROCESSING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY BIOREACTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL CULTURE MEDIA & REAGENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL CULTURE MEDIA & REAGENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CENTRIFUGES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CENTRIFUGES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CHROMATOGRAPHY SYSTEM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CHROMATOGRAPHY SYSTEM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY INCUBATORS & SHAKERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY INCUBATORS & SHAKERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY DOWNSTREAM BIOPROCESS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY DOWNSTREAM BIOPROCESS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY UPSTREAM BIOPROCESS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY UPSTREAM BIOPROCESS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CLINICAL OPERATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CLINICAL OPERATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY COMMERCIAL OPERATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY COMMERCIAL OPERATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 277. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 278. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 287. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 288. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 294. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 297. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 298. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 299. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 300. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 301. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 302. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 303. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 304. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 307. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 308. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 309. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 310. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 311. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 312. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 313. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 314. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 315. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 316. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 317. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 318. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 319. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 320. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 321. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 322. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 323. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 324. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 325. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 326. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 328. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 330. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 332. NETHERLANDS CONTINUOUS BIOPROCESSING MA